Esophageal squamous cell carcinoma(ESCC)lacks a standardized classification system,resulting in inconsistent clinical management and a suboptimal prognosis.This study addresses the urgent need for a robust consensus t...Esophageal squamous cell carcinoma(ESCC)lacks a standardized classification system,resulting in inconsistent clinical management and a suboptimal prognosis.This study addresses the urgent need for a robust consensus taxonomy to facilitate precision treatment for ESCC.We employed a network-based approach to elucidate the interconnections among eight existing classification systems,leading to the identification of four distinct consensus molecular subtypes(ECMSs):ECMS1-MET(metabolic),characterized by dysregulated metabolic pathways and NFE2L2 activation;ECMS2-CLS(classical),featuring upregulated cell cycle and canonical signaling pathways;ECMS3-IM(immunomodulatory),marked by robust immune activation and elevated PD-1 expression;and ECMS4-MES(mesenchymal),associated with mesenchymal transition,stromal activation,and VEGF signaling.To improve clinical applicability,we developed an image-based framework(imECMS)that utilizes spatial organization features(SOFs)quantified from autodelineated hematoxylin‒eosin(H&E)-stained whole-slide images through deep learning algorithms.The imECMS classifier assigns patients to one of the four ECMS subtypes,which correlate with distinct molecular characteristics,prognoses,and responses to neoadjuvant chemotherapy and immunotherapy.Validation across multiple independent cohorts confirmed that the imECMS accurately classifies ESCC subtypes from histopathological images,offering a robust and effective tool for precision medicine.In summary,the ECMS/imECMS subtyping systems we developed are the most robust frameworks for ESCC to date,providing clear biological insights and a foundation for clinical stratification and targeted therapies.展开更多
Increased rates of ribosome biogenesis have been recognized as hallmarks of many cancers and are associated with poor prognosis.Using a CRISPR synergistic activation mediator(SAM)system library targeting 89 ribosomal ...Increased rates of ribosome biogenesis have been recognized as hallmarks of many cancers and are associated with poor prognosis.Using a CRISPR synergistic activation mediator(SAM)system library targeting 89 ribosomal proteins(RPs)to screen for the most oncogenic functional RPs in human esophageal squamous cell carcinoma(ESCC),we found that high expression of RPS15 correlates with malignant phenotype and poor prognosis of ESCC.展开更多
基金supported by Shenzhen Medical Research Funds(C2303002)the National Natural Science Foundation of China(U21A20372,82341024,82172930,82302916,82103143,82573811)+13 种基金Shenzhen“San-Ming”Project of Medicine(SZSM202311014)the funds of Guangdong Basic and Applied Basic Research Foundation(2019B030302012)Major Program of Shenzhen Bay Laboratory(S201101004)Guangdong Provincial Natural Science Foundation General Project(2025A1515012310)National Science and Technology Major Project(2025ZD0544700,2025ZD0551700)the Science and Shanxi Province Higher Education“Billion Project”Science and Technology Guidance Project(SYBYRC-202506,SY-BYSL-2025018)Jiangxi Overseas High-Level Talent Project(20232BCJ25029)the Research Grants Council(No.14104223,11103921,14111522,C4024-22GF,R4007-23)of the Hong Kong Special Administrative Region,Chinaa startup fund(No.4937084)direct grant(No.2021.077,No.2024.147,2024.175)the Faculty Postdoctoral Fellowship Scheme(No.FPFS/24-25/053,FPFS/23-24/061C,FPFS/23-24/060,FPFS/22-23/026)Research Committee-Group Research Scheme 2022-23(No.WW/rc/grs2223/0560/23en)from the Chinese University of Hong Kongthe Fundamental Research Program of Shanxi Province(202303021221236)the China National Postdoctoral Program for Innovative Talents(BX20220214).
文摘Esophageal squamous cell carcinoma(ESCC)lacks a standardized classification system,resulting in inconsistent clinical management and a suboptimal prognosis.This study addresses the urgent need for a robust consensus taxonomy to facilitate precision treatment for ESCC.We employed a network-based approach to elucidate the interconnections among eight existing classification systems,leading to the identification of four distinct consensus molecular subtypes(ECMSs):ECMS1-MET(metabolic),characterized by dysregulated metabolic pathways and NFE2L2 activation;ECMS2-CLS(classical),featuring upregulated cell cycle and canonical signaling pathways;ECMS3-IM(immunomodulatory),marked by robust immune activation and elevated PD-1 expression;and ECMS4-MES(mesenchymal),associated with mesenchymal transition,stromal activation,and VEGF signaling.To improve clinical applicability,we developed an image-based framework(imECMS)that utilizes spatial organization features(SOFs)quantified from autodelineated hematoxylin‒eosin(H&E)-stained whole-slide images through deep learning algorithms.The imECMS classifier assigns patients to one of the four ECMS subtypes,which correlate with distinct molecular characteristics,prognoses,and responses to neoadjuvant chemotherapy and immunotherapy.Validation across multiple independent cohorts confirmed that the imECMS accurately classifies ESCC subtypes from histopathological images,offering a robust and effective tool for precision medicine.In summary,the ECMS/imECMS subtyping systems we developed are the most robust frameworks for ESCC to date,providing clear biological insights and a foundation for clinical stratification and targeted therapies.
基金The authors are grateful to Dr.Zhi Lu(Tsinghua University,China)for kindly providing RNA-seq analysis and ribosome-seq analysis technique direction.The authors are grateful to Dr.Yutaka Shimada(Kyoto University,Japan)for the ESCC cell lines.The authors appreciate Cong Liu(Sinsage Technology Co.LTD)for providing the Livecyte single-cell tracking imaging analysis system.The authors thank Novogene Bioinformatics Technology Co.,Ltd.,Beijing,for assistance during the Ribosome-seq analysis.This work was supported by the National Natural Science Foundation of China(82188102,81903025,82273453 and 82030089)National Key R&D Program of China(2021YFC2501000 and 2020YFA0803300)+1 种基金CAMS Innovation Fund for Medical Sciences(2021-1-I2M-1-018,2022-I2M-2-001 and 2021-I2M-1-067)the Fundamental Research Funds for the Central Universities(3332021091).
文摘Increased rates of ribosome biogenesis have been recognized as hallmarks of many cancers and are associated with poor prognosis.Using a CRISPR synergistic activation mediator(SAM)system library targeting 89 ribosomal proteins(RPs)to screen for the most oncogenic functional RPs in human esophageal squamous cell carcinoma(ESCC),we found that high expression of RPS15 correlates with malignant phenotype and poor prognosis of ESCC.
